ALK and non-small cell lung carcinoma: Alectinib (ALC) has been recognized as the prevailing initial therapy for patients diagnosed with advanced NSCLC who possess ALK gene alterations, particularly in cases where resistance emerges and subsequently results in clinical relapse.